Phio Pharmaceuticals Corp. (PHIO)
| Market Cap | 9.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.52M |
| Shares Out | 13.66M |
| EPS (ttm) | -1.04 |
| PE Ratio | n/a |
| Forward PE | 3.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,406,422 |
| Open | 0.709 |
| Previous Close | 0.708 |
| Day's Range | 0.650 - 0.753 |
| 52-Week Range | 0.620 - 2.470 |
| Beta | 1.83 |
| Analysts | Buy |
| Price Target | 6.12 (+760.8%) |
| Earnings Date | May 12, 2022 |
About PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that t...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for PHIO stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 760.76% from the latest price.
News
Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022
MARLBOROUGH, Mass. , May 16, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietar...
Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 MARLBOROUGH, Mass. , May ...
Phio Pharmaceuticals Announces Senior Leadership Personnel Change
MARLBOROUGH, Mass. , May 5, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary...
Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022
MARLBOROUGH, Mass. , May 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary...
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022
Marlborough, Mass., May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary ...
Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors
MARLBOROUGH, Mass. , May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary...
Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma
MARLBOROUGH, Mass. , April 26, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propriet...
Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunothera...
MARLBOROUGH, Mass. , April 18, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propriet...
3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes
Check these three penny stocks out as PHIO stock climbs The post 3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....
Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation
Phio Pharmaceuticals Corp (NASDAQ: PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4) The preclinical data exhibit...
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractor...
MARLBOROUGH, Mass. , April 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprieta...
Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update
Company transitioning into a clinical stage company with start of the first clinical study for lead program, PH-762. MARLBOROUGH, Mass.
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022
MARLBOROUGH, Mass., March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietar...
Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2
MARLBOROUGH, Mass., Feb. 22, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company developing the next generation of therapeutics based on its proprietar...
3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gains Today
We're seeing major movement from some hot penny stocks today and are diving into all the recent news that has them on the rise! The post 3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gains...
French Regulatory Authority Gives Green Signal To Phio Pharma's Melanoma Trial
The French National Agency for the Safety of Medicines and Health Products has signed off Phio Pharmaceuticals Corp's (NASDAQ: PHIO) clinical trial with its lead product candidate, PH-762 in melanoma. T...
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma
MARLBOROUGH, Mass., Jan. 11, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference
MARLBOROUGH, Mass., Jan. 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...
Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36...
MARLBOROUGH, Mass., Nov. 12, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
MARLBOROUGH, Mass., Nov. 10, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting
MARLBOROUGH, Mass., Oct. 18, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...
Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and C...
MARLBOROUGH, Mass., Oct. 7, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...
Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021
MARLBOROUGH, Mass., Sept. 30, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...
Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation
Phio Pharmaceuticals Corp (NASDAQ: PHIO) has announced preclinical results from a new study of a self-delivering RNAi (INTASYL) therapeutic platform. The data were presented at the European Society of M...
Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Target...
MARLBOROUGH, Mass., Sept. 16, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...